# OnCo record dordaviprone (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dordaviprone/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dordaviprone" ;
  schema:name "Dordaviprone"@en ;
  schema:description "Dordaviprone is the first drug ever approved for a childhood and young-adult brain tumour that had none, diffuse midline glioma with the H3 K27M mutation (August 2025)."@en ;
  schema:url <https://onco.cc/drugs/dordaviprone/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma>, <https://www.onclive.com/view/fda-approves-dordaviprone-for-diffuse-midline-glioma>, <https://doi.org/10.1200/JCO.23.01134> ;
  onco:status "approved" ;
  onco:modality "Small-molecule imipridone (ClpP agonist / DRD2 antagonist)" ;
  schema:alternateName "Modeyso" ;
  onco:approval "US 2025: Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)" ;
  onco:acceleratedApproval "US 2025-08-06: Treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy." ;
  onco:related <https://onco.cc/biomarkers/h3-k27m/> ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:companies <https://onco.cc/companies/jazz/> ;
  onco:terms <https://onco.cc/terms/h3k27m/>, <https://onco.cc/terms/blood-brain-barrier/>, <https://onco.cc/terms/accelerated-approval/> ;
  onco:trials <https://onco.cc/trials/action-dmg/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-arrillaga-romany-j-clin-oncol/> .